vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and TEJON RANCH CO (TRC). Click either name above to swap in a different company.

TEJON RANCH CO is the larger business by last-quarter revenue ($21.1M vs $14.7M, roughly 1.4× IRIDEX CORP). On growth, TEJON RANCH CO posted the faster year-over-year revenue change (17.7% vs -69.7%). Over the past eight quarters, TEJON RANCH CO's revenue compounded faster (68.8% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Tejon Ranch Company, based in Lebec, California, is one of the largest private landowners in California. The company was incorporated in 1936 to organize the ownership of a large tract of land that was consolidated from four Mexican land grants acquired in the 1850s and 1860s by ranch founder Edward Fitzgerald Beale.

IRIX vs TRC — Head-to-Head

Bigger by revenue
TRC
TRC
1.4× larger
TRC
$21.1M
$14.7M
IRIX
Growing faster (revenue YoY)
TRC
TRC
+87.4% gap
TRC
17.7%
-69.7%
IRIX
Faster 2-yr revenue CAGR
TRC
TRC
Annualised
TRC
68.8%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
TRC
TRC
Revenue
$14.7M
$21.1M
Net Profit
$1.6M
Gross Margin
37.2%
30.6%
Operating Margin
10.9%
Net Margin
7.5%
Revenue YoY
-69.7%
17.7%
Net Profit YoY
-64.7%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
TRC
TRC
Q4 25
$14.7M
$21.1M
Q3 25
$12.5M
$12.0M
Q2 25
$13.6M
$8.3M
Q1 25
$11.9M
$8.2M
Q4 24
$12.7M
$17.9M
Q3 24
$11.6M
$10.9M
Q2 24
$12.6M
$5.7M
Q1 24
$11.8M
$7.4M
Net Profit
IRIX
IRIX
TRC
TRC
Q4 25
$1.6M
Q3 25
$-1.6M
$1.7M
Q2 25
$-994.0K
$-1.7M
Q1 25
$-1.7M
$-1.5M
Q4 24
$-834.0K
$4.5M
Q3 24
$-1.9M
$-1.8M
Q2 24
$-2.7M
$957.0K
Q1 24
$-3.5M
$-914.0K
Gross Margin
IRIX
IRIX
TRC
TRC
Q4 25
37.2%
30.6%
Q3 25
32.1%
28.4%
Q2 25
34.5%
40.9%
Q1 25
42.5%
15.0%
Q4 24
44.0%
42.9%
Q3 24
37.3%
22.9%
Q2 24
40.7%
45.3%
Q1 24
37.9%
0.3%
Operating Margin
IRIX
IRIX
TRC
TRC
Q4 25
10.9%
Q3 25
-11.3%
-16.9%
Q2 25
-6.9%
-48.8%
Q1 25
-1.7%
-50.7%
Q4 24
-3.9%
11.9%
Q3 24
-16.1%
-34.9%
Q2 24
-20.9%
-62.4%
Q1 24
-28.0%
-53.8%
Net Margin
IRIX
IRIX
TRC
TRC
Q4 25
7.5%
Q3 25
-12.6%
14.0%
Q2 25
-7.3%
-20.6%
Q1 25
-14.2%
-17.8%
Q4 24
-6.6%
25.0%
Q3 24
-16.7%
-16.9%
Q2 24
-21.2%
16.8%
Q1 24
-29.5%
-12.3%
EPS (diluted)
IRIX
IRIX
TRC
TRC
Q4 25
$0.05
Q3 25
$-0.09
$0.06
Q2 25
$-0.06
$-0.06
Q1 25
$-0.10
$-0.05
Q4 24
$-0.05
$0.16
Q3 24
$-0.12
$-0.07
Q2 24
$-0.16
$0.04
Q1 24
$-0.21
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
TRC
TRC
Cash + ST InvestmentsLiquidity on hand
$6.0M
$9.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$475.2M
Total Assets
$29.2M
$630.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
TRC
TRC
Q4 25
$6.0M
$9.5M
Q3 25
$5.6M
$3.6M
Q2 25
$6.8M
$2.5M
Q1 25
$7.2M
$12.3M
Q4 24
$2.4M
$39.3M
Q3 24
$3.9M
$27.4M
Q2 24
$4.1M
$33.0M
Q1 24
$5.4M
$35.6M
Total Debt
IRIX
IRIX
TRC
TRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
TRC
TRC
Q4 25
$475.2M
Q3 25
$4.7M
$473.2M
Q2 25
$6.1M
$471.5M
Q1 25
$852.0K
$472.5M
Q4 24
$2.1M
$473.6M
Q3 24
$2.6M
$468.3M
Q2 24
$4.2M
$469.2M
Q1 24
$6.5M
$467.4M
Total Assets
IRIX
IRIX
TRC
TRC
Q4 25
$29.2M
$630.5M
Q3 25
$28.4M
$629.6M
Q2 25
$31.6M
$618.5M
Q1 25
$34.2M
$614.6M
Q4 24
$29.1M
$608.0M
Q3 24
$30.2M
$598.0M
Q2 24
$31.2M
$590.8M
Q1 24
$34.1M
$581.6M
Debt / Equity
IRIX
IRIX
TRC
TRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
TRC
TRC
Operating Cash FlowLast quarter
$6.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.88×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
TRC
TRC
Q4 25
$6.1M
Q3 25
$-1.2M
$-2.4M
Q2 25
$-397.0K
$-381.0K
Q1 25
$-1.1M
$-1.3M
Q4 24
$-1.2M
$14.3M
Q3 24
$-3.1M
$2.1M
Q2 24
$-1.3M
$-1.8M
Q1 24
$-1.6M
$777.0K
Free Cash Flow
IRIX
IRIX
TRC
TRC
Q4 25
Q3 25
$-1.2M
$-14.6M
Q2 25
$-410.0K
$-20.0M
Q1 25
$-1.2M
$-18.9M
Q4 24
$-1.2M
$-42.9M
Q3 24
$-3.1M
$-16.8M
Q2 24
$-15.8M
Q1 24
$-1.7M
$-7.3M
FCF Margin
IRIX
IRIX
TRC
TRC
Q4 25
Q3 25
-9.4%
-122.2%
Q2 25
-3.0%
-240.6%
Q1 25
-9.8%
-230.1%
Q4 24
-9.8%
-239.3%
Q3 24
-26.5%
-155.2%
Q2 24
-277.2%
Q1 24
-14.0%
-99.0%
Capex Intensity
IRIX
IRIX
TRC
TRC
Q4 25
Q3 25
0.1%
102.3%
Q2 25
0.1%
236.0%
Q1 25
0.1%
213.7%
Q4 24
0.1%
319.1%
Q3 24
0.0%
174.3%
Q2 24
0.0%
245.5%
Q1 24
0.0%
109.5%
Cash Conversion
IRIX
IRIX
TRC
TRC
Q4 25
3.88×
Q3 25
-1.43×
Q2 25
Q1 25
Q4 24
3.19×
Q3 24
Q2 24
-1.88×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons